IBM, Coriell Life Sciences and CareKinesis have launched a cloud-based service intended to analyze how high-risk individuals respond to specific medications and drug treatments.

In collaboration with IBM, Coriell Life Sciences built a cloud-based solution that stores data in Coriell Life Sciences' GeneVault. The GeneVault stores and manages millions of genetic data points. This data is then interpreted and shared with physicians through CareKinesis, which layers additional medication management decision factors into a tool for doctors within Corriell’s Program for All Inclusive Care of the Elderly organizations.

Physicians, healthcare providers and medical experts can access a patient's genomic interpretation via Web-connected device via the interfaced CareKinesis and Coriell Life Sciences systems.

For example, a cardiologist may consider prescribing a patient a popular blood-thinning drug, but may be concerned about the potential for an adverse reaction. The PACE team decides to conduct a test to assess if the participant will respond to the medication being considered. The test is run by swabbing the inside of the patient's cheek to collect a tiny amount of genetic material, which goes to Coriell Life Sciences for testing.

Results are analyzed and interpreted for their impact on drug response. The resulting report is then transmitted to the doctor giving guidance on whether the patient can safely use the drug. CareKinesis supports the process by making pharmacotherapy recommendations based on these results. The data can be used at any time it is needed in the future for pharmacotherapy prescribing decisions.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access